Elo Mutual Pension Insurance Co Sells 505 Shares of Becton, Dickinson and Company (NYSE:BDX)

Elo Mutual Pension Insurance Co decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 1.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,951 shares of the medical instruments supplier’s stock after selling 505 shares during the period. Elo Mutual Pension Insurance Co’s holdings in Becton, Dickinson and Company were worth $6,065,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Livelsberger Financial Advisory bought a new position in shares of Becton, Dickinson and Company in the fourth quarter worth approximately $27,000. OLD Point Trust & Financial Services N A purchased a new position in Becton, Dickinson and Company in the 4th quarter worth approximately $29,000. Scarborough Advisors LLC bought a new position in Becton, Dickinson and Company in the 4th quarter valued at approximately $32,000. Rise Advisors LLC purchased a new stake in Becton, Dickinson and Company during the 1st quarter valued at $38,000. Finally, ICA Group Wealth Management LLC bought a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth $42,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Performance

BDX opened at $231.58 on Thursday. The company’s 50 day moving average is $235.23 and its 200 day moving average is $235.54. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. The company has a market cap of $66.93 billion, a price-to-earnings ratio of 51.01, a PEG ratio of 1.91 and a beta of 0.42. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $269.52.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The firm had revenue of $4.99 billion during the quarter, compared to the consensus estimate of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.96 EPS. On average, equities research analysts predict that Becton, Dickinson and Company will post 13.1 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be given a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a yield of 1.64%. The ex-dividend date is Monday, September 9th. Becton, Dickinson and Company’s payout ratio is 83.70%.

Wall Street Analysts Forecast Growth

BDX has been the topic of a number of research analyst reports. Stifel Nicolaus upped their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Raymond James lowered their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. The Goldman Sachs Group began coverage on shares of Becton, Dickinson and Company in a research note on Thursday, May 30th. They issued a “buy” rating and a $274.00 price target for the company. Evercore ISI decreased their price objective on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Finally, StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $279.50.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.